Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 23andMe Holding Co. ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including... see more

Recent & Breaking News (NDAQ:ME)

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

GlobeNewswire March 9, 2023

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

GlobeNewswire February 28, 2023

23andMe to Present at Upcoming Investor Conferences

GlobeNewswire February 22, 2023

23andMe Reports FY2023 Third Quarter Financial Results

GlobeNewswire February 8, 2023

23andMe to Report FY2023 Third Quarter Financial Results

GlobeNewswire January 26, 2023

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

GlobeNewswire December 1, 2022

23andMe Reports FY2023 Second Quarter Financial Results

GlobeNewswire November 7, 2022

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

GlobeNewswire November 7, 2022

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

GlobeNewswire October 27, 2022

23andMe to Report FY2023 Second Quarter Financial Results

GlobeNewswire October 24, 2022

23andMe to Present at Upcoming Investor Conferences

GlobeNewswire October 12, 2022

23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

GlobeNewswire October 5, 2022

Daniel Chu Joins 23andMe as Chief Product Officer

GlobeNewswire September 19, 2022

23andMe Reports FY2023 First Quarter Financial Results

GlobeNewswire August 8, 2022

23andMe to Report FY2023 First Quarter Financial Results

GlobeNewswire July 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF

PR Newswire July 21, 2022

23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results

GlobeNewswire May 26, 2022

Quarterhill Appoints John Karnes as CFO

PR Newswire May 24, 2022

23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

GlobeNewswire May 12, 2022

23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

GlobeNewswire March 15, 2022